866-997-4948(US-Canada Toll Free)

Belviq (Obesity) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Oct 2013

Category :

Metabolic Disorders

No. of Pages : 48 Pages


After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Belviq (lorcaserin), a product of Arena Pharmaceuticals, was the second anti-obesity drug to arrive in the market after a long pharmacotherapy hiatus, coming nine months after the launch of Vivus Qsymia as one of the main competitors. It is not yet approved in any of the European markets, Canada, Brazil, or Japan. GlobalData forecasts that Belviq will not reach the European market until 2018, the Canadian market until 2017, and the Brazilian market until 2016. Arena and its marketing partner, Eisai, have given no indication of any plans to launch Belviq in Japan.

Scope

  • Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Belviq including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Belviq for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for obesity.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Belviq performance
  • Obtain sales forecast for Belviq from 2012-2022 in top eight countries (the US, France, Germany, Italy, Spain, China, Brazil and Canada)
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 14
3.1.4 Quality of Life 15
3.2 Symptoms 15

4 Disease Management 16
4.1 Treatment Overview 16

5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 26

6 Belviq (lorcaserin) 28
6.1 Overview 28
6.2 Efficacy 30
6.3 Safety 31
6.4 SWOT Analysis 32
6.5 Forecast 32

7 Appendix 34
7.1 Bibliography 34
7.2 Abbreviations 37
7.3 Research Methodology 38
7.4 Forecasting Methodology 38
7.4.1 Percent Drug-Treated Obesity Patients 39
7.4.2 Launch and Patent Expiry Dates 39
7.4.3 General Pricing Assumptions 40
7.4.4 Individual Drug Assumptions 40
7.4.5 Generic Erosion 40
7.5 Physicians, Specialists, and Payers Included in This Study 41
7.6 About the Authors 44
7.6.1 Analysts 44
7.6.2 Therapy Director - CVMD and Infectious Disease 45
7.6.3 Director - Medical Devices 45
7.6.4 Global Head of Healthcare 46
7.7 About GlobalData 47
7.8 Disclaimer 47

List of Table


Table 1: Target Pathways in the Treatment of Obesity 14
Table 2: Symptoms of Obesity 15
Table 3: Treatment Guidelines for Obesity 19
Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013 20
Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk 21
Table 6: Bariatric Treatment Attributes 25
Table 7: Leading Drug Treatments for Obesity, 2013 26
Table 8: Marketed Obesity Treatment Devices by Type 27
Table 9: Product Profile - Belviq 30
Table 10: Belviq SWOT Analysis, 2013 32
Table 11: Global Sales Forecasts ($m) for Belviq, 2012-2022 33
Table 12: Key Launch Dates - Belviq 39
Table 13: Key Patent Expiries - Belviq 39

List of Chart


Figure 1: Treatment Algorithm for Obesity 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *